Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | C1S | P09871 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.46 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL241785 | 0.83 | PARP1 (0.68) | PARP1ALDH1A1TP53HPGDSMN1; SMN2 | |
| SCHEMBL30153175 | 0.83 | PARP1 (0.68) | PARP1ALDH1A1TP53HPGDSMN1; SMN2 | |
| SCHEMBL6670439 | 0.83 | PARP1 (0.68) | PARP1ALDH1A1TP53HPGDSMN1; SMN2 | |
| SCHEMBL8681033 | 0.81 | PARP1 (0.65) | PARP1ALDH1A1TP53HPGDSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL27869733 | 0.81 | PARP1 (0.65) | PARP1ALDH1A1TP53HPGDSMN1; SMN2 | |
| SCHEMBL29537403 | 0.81 | PARP1 (0.65) | PARP1ALDH1A1TP53HPGDSMN1; SMN2 | |
| SCHEMBL5023 | 0.81 | PARP1 (0.65) | PARP1ALDH1A1TP53HPGDSMN1; SMN2 | |
| SCHEMBL23079025 | 0.79 | PARP1 (0.69) | PARP1ALDH1A1TP53HPGDSMN1; SMN2 | |
| SCHEMBL9586434 | 0.79 | PARP1 (0.63) | PARP1ALDH1A1TP53HPGDSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL698593 | 0.79 | PARP1 (0.63) | PARP1ALDH1A1TP53HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110184173-A1 | Pyripyropene Derivatives Having An ACAT2-Inhibiting Activity | THE KITASATO INSTITUTE (JP) | 2011-07-28 | — | — | US | claimed |
| EP-2228376-A1 | PYRIPYROPENE DERIVATIVE HAVING ACAT2-INHIBITING ACTIVITY | The Kitasato Institute (JP) | 2010-09-15 | — | — | EP | claimed |
| US-20100179217-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2010-07-15 | — | — | US | claimed |
| US-7728001-B2 | Opioid receptor ligands and methods for their preparation | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2010-06-01 | — | — | US | claimed |
| US-20090088466-A1 | OPIOID RECEPTOR LIGANDS | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2009-04-02 | — | — | US | claimed |
| WO-2008055261-A2 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2008-05-08 | — | — | WO | claimed |
| WO-2006138589-A2 | OPIOID RECEPTOR LIGANDS | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2006-12-28 | — | — | WO | claimed |
| WO-2006031782-A2 | SALVINORIN DERIVATIVES AS OPIOID RECEPTOR LIGANDS | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2006-03-23 | — | — | WO | claimed |
| US-20060058264-A1 | Opioid receptor ligands and methods for their preparation | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2006-03-16 | — | — | US | claimed |
| WO-2023210623-A1 | HALOALKYL SULFONE ANILIDE COMPOUND AND HERBICIDE CONTAINING SAME | 株式会社エス・ディー・エス バイオテック | 2023-11-02 | — | — | WO | disclosed |
| US-10022454-B2 | Functionalized phosphorodiamites for therapeutic oligonucleotide synthesis | LIPOSCIENCES, LLC (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170224832-A9 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | PETERSEN SCOTT G (US) | 2017-08-10 | — | — | US | disclosed |
| EP-3067359-A1 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | Petersen, Scott G. (US) | 2016-09-14 | — | — | EP | disclosed |
| US-9428494-B2 | Therapeutic compounds | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2016-08-30 | — | — | US | disclosed |
| WO-1991005549-A1 | BENZOHETEROCYCLIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-05-02 | — | — | WO | disclosed |
| EP-0379174-A2 | 2,3-Dihydro-3,3-dimethyl-5-trifluoromethanesulfonyloxybenzofurans, process for producing them and herbicides containing them | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-07-25 | — | — | EP | disclosed |
| US-4591459-A | Intermediates for 6-(aminoacyloxymethyl) penicillanic acid 1,1-dioxides | PFIZER INC. (US) | 1986-05-27 | — | — | US | disclosed |
| US-4503040-A | 6-(Aminoacyloxymethyl)penicillanic acid 1,1-dioxides as beta-lactamase inhibitors | PFIZER INC. (US) | 1985-03-05 | — | — | US | disclosed |
| US-4452796-A | ANTIBIOTICS | PFIZER INC. (US) | 1984-06-05 | — | — | US | disclosed |
| US-3936462-A | CNS DEPRESSANT, ANALGESIC | STERLING DRUG INC. (US) | 1976-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179217-A1 | THERAPEUTIC COMPOUNDS | OPRL1, OPRK1, OPRM1 | PARP1 4643/4885ALDH1A1 689/4885TP53 4851/4885 |
| US-10022454-B2 | Functionalized phosphorodiamites for therapeutic oligonucleotide synthesis | NCL, PHOSPHO1, POLN | PARP1 411/4885ALDH1A1 4411/4885TP53 1169/4885 |
| US-20110184173-A1 | Pyripyropene Derivatives Having An ACAT2-Inhibiting Activity | ACAT2, ACAT1, AGPAT2 | PARP1 4377/4885ALDH1A1 1202/4885TP53 2452/4885 |
| US-20170224832-A9 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | POLN, SARNP, NCL | PARP1 218/4885ALDH1A1 4308/4885TP53 433/4885 |
| US-20090088466-A1 | OPIOID RECEPTOR LIGANDS | OPRL1, OPRK1, OPRM1 | PARP1 4804/4885ALDH1A1 769/4885TP53 4868/4885 |
| US-20060058264-A1 | Opioid receptor ligands and methods for their preparation | OPRL1, OPRM1, OPRK1 | PARP1 4660/4885ALDH1A1 703/4885TP53 4874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.